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A b s t r a c t
Introduction: The 25-item National Eye Institute Visual Function Question-
naire (NEI VFQ-25) was designed to measure the vision-related quality of life 
(QoL). We aimed to assess the effect of disease duration, disease type (i.e., 
acute vs. chronic and unilateral vs. bilateral), and selected sociodemograph-
ic data on the QoL of patients with central serous chorioretinopathy (CSC).
Material and methods: The study included 79 patients diagnosed with CSC. 
The QoL was assessed using the NEI VFQ-25. The statistical analysis was 
performed using IBM SPSS Statistics 24.
Results: A significant positive correlation was found between deterioration 
in peripheral vision as assessed by the NEI VFQ-25 and duration of CSC 
(r = –0.22, p = 0.046). Compared with women, men obtained higher scores 
on the scales assessing general health, mental health, ocular pain and role 
limitations (p = 0.018, p = 0.027, p = 0.009 and p = 0.007, respectively). 
Patients with acute CSC reported higher levels of social functioning as com-
pared with those with chronic CSC (p = 0.04). There were no differences in 
any of the scales between patients with unilateral and bilateral CSC. Elderly 
patients obtained lower scores on 9 of the 12 analyzed scales, as compared 
with younger patients (p < 0.05).
Conclusions: Patients with CSC do not assess their QoL in negative terms, 
which may be related to the fact that the disease presents with transient 
symptoms. However, the QoL deteriorated with longer disease duration. 
Men with CSC have better vision-related QoL than women.
Key words: health-related quality of life, vision disorders, retina, 
questionnaire.
Introduction
Central serous chorioretinopathy (CSC) ranks among the most com-
mon sight-threatening retinopathies, together with age-related macular 
degeneration (AMD), diabetic retinopathy and branch retinal vein occlu-
sion [1, 2]. The incidence of the disease, as estimated by Kitzmann et al. 
[3], is 9.9 (95% confidence interval (CI): 7.4–12.4) per 100,000 in men 
and 1.7 (95% CI: 0.7–2.7) in women. The limited literature data suggest 
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comparable rates of CSC across white, Asian, and 
African American populations [4–6]. A  study on 
the prevalence of retinal diseases in older adults 
in Poland reported that chronic CSC constitutes 
less than 1% of all diagnoses [7]. The condition 
is caused by a  central retinal detachment, sec-
ondary to damage of retinal pigment epithelium 
(Figure 1), and it is characterized by metamorph-
opsia and painless loss of central vision [8]. Most 
published reports differentiate between an acute 
and a  chronic form of CSC using a  threshold of 
6 months since diagnosis [9].
Central serous chorioretinopathy was first 
described in detail by von Graefe in 1986 [10]. 
Nevertheless, its pathogenesis remains unclear 
[11–13]. The age of affected patients varies in 
the literature, with a recent epidemiological study 
reporting a  mean age ranging between 39 and 
51 years [14]. Also, more common occurrence 
of CSC has been associated with male sex, ste-
roid therapy, general hypertension, alcohol abuse, 
Cushing disease, Helicobacter pylori infection, preg-
nancy, cigarette smoking, and stress [12, 15, 16]. 
Central serous chorioretinopathy is a  self-limited 
disorder with a favorable visual prognosis in most 
cases; nonetheless, 31% of CSC patients experi-
ence disease recurrence within a median time of 
1.3 years (range: 0.4–18.2) [17]. In 10% to 20% of 
cases, progressive visual loss may develop [18, 19]. 
Recent reports have indicated that the assess-
ment of the quality of life (QoL) is an essential 
tool for estimating the burden of various diseas-
es [20–22]. Quality of life is defined by the World 
Health Organization as “an individual’s percep-
tion of their position in life in the context of the 
culture and value systems in which they live and 
in relation to their goals, expectations, standards 
and concerns” [23, 24]. So far, only a few studies 
have been published on the QoL of patients with 
CSC [15, 25–27]. Patients with CSC were general-
ly reported to have worse vision-related QoL than 
people without this disease [25, 26]. 
The goal of CSC treatment is similar to that of 
other types of treatment for sight-threatening eye 
diseases. For example, according to the European 
Glaucoma Society, glaucoma treatment is aimed at 
maintaining the patient’s visual function and re-
lated quality of life, at a sustainable cost [28, 29].
To date, assessment of vision-related QoL, 
based on the National Eye Institute Vision Func-
tion Questionnaire (NEI VFQ-25), of only 30 pa-
tients with chronic CSC has been reported [25]. 
Thus, the main purpose of our study was to an-
alyze QoL of a  large group of patients with CSC, 
depending on the duration of the disease, its form 
(i.e., unilateral vs. bilateral, and acute vs. chron-
ic) and selected socio-demographic data (i.e., age, 
sex, marital status, and place of residence).
Material and methods
The study included 79 adult white patients 
(60 men and 19 women) diagnosed with CSC at 
the Department of Ophthalmology, Jagiellonian 
University in Krakow, Poland, between January 
and December 2017. 
The diagnosis of CSC was based on typical 
findings in the fundus of the eye documented by 
digital photography, fluorescein angiography, and 
optical coherence tomography. Patients were clas-
sified into 2 groups: with acute CSC (disease du-
ration < 6 months) and with chronic CSC (disease 
duration ≥ 6 months).
The QoL was evaluated with the NEI VFQ-25, 
version 2000, which has been validated in Poland 
[30]. RAND Corporation granted permission to 
use the NEI VFQ-25 without any charge to all re-
searchers on condition that they identify the mea-
sure as such in all their publications [31]. Specific 
information is provided on the cover page of the 
NEI VFQ-25 itself. The responses of patients were 
scored in accordance with the NEI VFQ-25 calcu-
lation algorithm [31]. The NEI VFQ-25 consists of 
25 questions assessing the patient’s general 
health, general vision, ocular pain, near vision, dis-
tance vision, peripheral vision, color vision, driving, 
as well as vision-specific social functioning, mental 
health, role difficulties, and dependency [30, 31]. 
The content of the questions was based on the 
results from a series of focus groups including pa-
Figure 1. Swept source optical coherence tomography image of the macula showing the subretinal fluid under the 
neurosensory retina concomitant with pigmented epithelium detachment (A), proper macular morphology of the 
contralateral eye (B)
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tients with specific eye conditions such as AMD, 
glaucoma, age-related cataracts, cytomegalovirus 
retinitis, or diabetic retinopathy [31]. The response 
scales were scored as follows: for questions 1 to 16 
– from the most positive to the most negative; and 
for questions 17 to 25 – from the most negative to 
the most positive [32]. In our procedures, we fol-
lowed the NEI VFQ manual of operations [31]. The 
questionnaire subscale scores were an average of 
the questions in the subscale changed to a 0 to 
100 scale, where 100 denoted the best possible 
score on the measure (best visual functioning) and 
0 represented the worst possible score (worst visu-
al functioning) [31, 32]. The final NEI VFQ-25 score 
was an unweighted average of the responses to all 
questions except the one pertaining to the gener-
al health evaluation (question number 1) [31]. Of 
note, the general health item is reported as a sep-
arate score to reflect an overall health condition 
in population-based studies and enable a compar-
ison for NEI VFQ-25 respondents [31].
The study was approved by the Bioeth-
ics Committee of Jagiellonian University (No. 
122.6120.266.2016). All patients provided written 
informed consent to participate in the study.
Statistical analysis
Qualitative data were presented as counts 
and percentages. Quantitative data were given as 
means and standard deviations (SD) for normally 
distributed variables and medians and quartiles 
for those with non-normal distribution. The nor-
mality of quantitative variables was tested using 
the Kolmogorov-Smirnov test and inspection of 
box plots and Q-Q plots. Quantitative variables 
were compared between the two groups using 
the Mann-Whitney test. The strength of the rela-
tionship between two interval variables was es-
timated using the Pearson correlation coefficient 
(r) for linearly related variables and the Spearman 
correlation coefficient (rho) for nonlinearly relat-
ed ones. Relationships between two quantitative 
variables were presented using scatterplots, and 
the shape of the relationship was drawn using the 
loess curve. A p-value of less than 0.05 was con-
sidered significant. The statistical analysis of the 
collected material was performed using the IBM 
SPSS Statistics 24 software for Windows.
Results 
The study included 60 (76%) men and 19 (24%) 
women. The mean age of patients was 46.7 ±9.0 
years. The mean duration of symptoms was 44.9 
±45.6 months. Acute CSC was diagnosed in 24 
(30%) patients, and chronic CSC in 55 (70%). In 
61 (77%) patients, the disease affected one eye, 
and in 18 (23%) patients, both eyes. There were 
28 (35%) patients living outside of the city and 
51 (65%) patients living in the city. Sixteen (20%) 
patients were single, while 63 (80%) were in a sta-
ble relationship.
The highest scores were noted for the fol-
lowing scales of the questionnaire: color vision, 
dependence, social functioning, and peripheral 
vision. The lowest values were recorded for gen-
eral health and general vision. Detailed data for 
the individual QoL scales in the study group are 
shown in Table I.
There were no correlations between any of 
the QoL scales and unilateral or bilateral CSC 
(p > 0.05). Patients with acute CSC scored higher 
only on the social functioning scale as compared 
with patients with chronic CSC (p = 0.04). 
We did not observe any significant relation-
ships between disease duration and QoL, except 
for the peripheral vision scale (p < 0.05). The score 
for peripheral vision assessment decreased with 
disease duration (r = –0.22, p = 0.046; Figure 2).
A  significant relationship was observed be-
tween sex and general health, ocular pain, men-
tal health, and role difficulties. Men scored higher 
than women on all these scales. Detailed data are 
shown in Table II. 
Interestingly, our analysis revealed a  strong 
negative correlation between age and the scores 
on 9 of the 12 questionnaire scales (p < 0.05): 
the patients’ assessment of their general health 
(rho = –0.45, p < 0.001), near vision (rho = –0.44, 
p < 0.001), distance vision (rho = –0.41, p < 0.001), as 
well as vision-specific mental health (rho = –0.32, 
Table I. Results of quality of life scales from the 25-
item National Eye Institute Visual Function Ques-
tionnaire (NEI VFQ-25) for the study group. Data 
are shown as median and interquartile range (Me 
(IQR)) for non-normally distributed variables
Quality of life scale Patients with CSC
General health 50.00 (25.00–75.00)
General vision 60.00 (60.00–80.00)
Ocular pain 75.00 (62.50–87.50)
Near activities 75.00 (58.33–83.33)
Distance activities 83.33 (75.00–100.00)
Social functioning 100.00 (87.50–100.00)
Mental health 75.00 (62.50–87.50)
Role difficulties 75.00 (50.00–87.50)
Dependency 100.00 (91.67–100.00)
Driving ability 83.33 (60.42–91.67)
Color vision 100.00 (100.00–100.00)
Peripheral vision 100.00 (75.00–100.00)
CSC – central serous chorioretinopathy.
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p = 0.004), role difficulties (rho = –0.32, p = 0.005), 
dependency (rho = –0.25, p = 0.024), color vision 
(rho = –0.27, p = 0.016), peripheral vision (rho = –0.22, 
p = 0.048), and social functioning (rho = –0.32, p = 
0.005) (Figure 3).
We did not observe any relationship between 
the scores on any of the questionnaire scales and 
the place of residence or marital status (p > 0.05).
Discussion
Studies published to date indicate that the 
QoL of patients with CSC is lower than that of 
the non-CSC population [25, 26]. Lajmi et al. [27] 
reported that CSC affects the psychological state 
and QoL of generally young and professional-
ly active individuals. This can impair their work 
performance and cause temporary or permanent 
disability [27].
Sahin et al. [26] analyzed psychological symp-
toms and QoL in a group of 30 patients with acute 
CSC. The authors used the Symptom Check List-
90 Revised for psychological evaluation and Short 
Form 36 for QoL assessment [26]. In turn, Türkcü 
et al. [25] investigated 30 patients with chronic 
CSC, using the NEI VFQ-25. Both Sahin et al. [26] 
and Türkcü et al. [25] found that CSC reduces the 
QoL of affected patients.
It was reported that most cases of acute CSC 
resolve spontaneously [17]. Some patients, how-
ever, experience recurrent or chronically persistent 
macular subretinal fluid. In our study, we explored 
a  potential relationship between the respective 
questionnaire scales and disease duration. In our 
analysis, duration of CSC was not associated with 
any of the QoL scales except for peripheral vision. 
Interestingly, this may be explained by the fact that 
the scores of individual scales did not vary consider-
ably and tended to concentrate in the upper ranges. 
However, our analysis indicates that the condition 
of patients with both acute and chronic CSC is fa-
vorable. In a  prospective study with a  12-month 
follow-up, Breukink et al. [15] assessed the QoL of 
36 patients with CSC. They used the NEI VFQ-39, which 
is an extended version of the NEI VFQ-25 used in our 
analysis. Contrary to our observations, they found 
that the QoL of patients significantly deteriorated in 
almost all categories along with disease duration, as 
compared with controls [15]. This discrepancy may be 
related to the cross-sectional design of our study.
In a  study by Türkcü et al. [25], patients with 
chronic CSC obtained worse scores on the NEI 
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Figure 2. Scatterplot showing the relationship be-
tween peripheral vision and duration of central 
















Table II. Correlation between quality of life and sex of CSC patients. Data are shown as median and 1st and 3rd 
quartiles (Me (Q1–Q3)) for non-normally distributed variables
Variable Men with CSC Women with CSC P-value
General health 50 (50–75) 50 (25–50) 0.018
General vision 60 (60–80) 60 (40–80) 0.160
Ocular pain 75 (63–94) 63 (50–75) 0.027
Near activities 75 (58–88) 67 (50–83) 0.373
Distance activities 92 (75–100) 83 (67–92) 0.064
Social functioning 100 (88–100) 100 (88–100) 0.777
Mental health 78 (69–88) 69 (56–69) 0.009
Role difficulties 75 (56–88) 50 (25–75) 0.007
Dependency 100 (88–100) 100 (92–100) 0.616
Driving ability 83 (67–92) 67 (58–83) 0.216
Color vision 100 (100–100) 100 (100–100) 0.749
Peripheral vision 100 (75–100) 100 (75–100) 0.835
CSC – central serous chorioretinopathy.
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Figure 3. Scatterplots showing the relationship between age and respective scales of the 25-item National Eye 
Institute Visual Function Questionnaire (NEI VFQ-25)
rho = –0.45, p < 0.001
rho = –0.41, p < 0.001
rho = –0.32, p = 0.004
rho = –0.44, p < 0.001
rho = –0.32, p = 0.005
rho = –0.32, p = 0.005
VFQ-25 scales except for general health, as com-
pared with controls. Similarly, in our study, the 
score on the social functioning scale was lower 
for patients with chronic CSC than for those with 
acute CSC. This may be explained by the worsen-
ing of vision function associated with long disease 
duration. 
Our study did not reveal any relationship be-
tween the QoL and either the unilateral or bilat-
eral form of CSC. This may be associated with 
the lack of serous retinal detachment in the 
macula and vision deterioration in the affected 
eye during remission. Moreover, asymptomatic 
patients may have presented a  single or multi-
ple episodes of extramacular serous detachment. 
This phenomenon is also commonly observed in 
the contralateral eye of CSC patients [33]. How-
ever, further research is needed to confirm this 
hypothesis. Interestingly, in neovascular AMD, 
the vision-related QoL was lower in patients with 
both eyes affected than in those with the involve-
ment of a single eye [34]. This may be due to the 
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progressive nature of this maculopathy with no 
periods of remission.
Nickels et al. [29] conducted a  large popula-
tion-based study of mainly Caucasian ethnicity to 
provide a reference for comparison for future re-
search evaluating the effect of eye diseases on the 
QoL. In line with the study by Nickels et al. [29], 
our results support the association of vision-relat-
ed QoL with age and sex [35]. We observed the 
strongest association between a worse QoL and 
older age (lower scores for 9 of the 12 scales in 
the NEI VFQ-25). Based on the literature, it can be 
speculated that women report more medical prob-
lems and more diseases than men, and they tend 
to assess their health in more negative terms [36, 
37]. In keeping with other studies, we found that 
female patients rated their general health, men-
tal health, role difficulties, and ocular pain worse 
than men. Based on our sociodemographic data, 
we did not detect any relationship between the 
QoL and marital status and place of residence.
Our study has several limitations, including its 
cross-sectional design and the fact that it was 
conducted at a single time point.
In conclusion, we demonstrated that patients 
with CSC do not assess their QoL in negative 
terms. This may be related to the fact that the 
disease presents with transient symptoms. How-
ever, the QoL was shown to decrease with long 
duration of CSC. Our study emphasizes that the 
possible impact of CSC on the QoL should not be 
underestimated. 
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